The Delhi High Court ordered Sun Pharmaceutical Industries to obtain judicial permission before launching its generic version of semaglutide. This directive follows a patent infringement lawsuit filed by Danish drugmaker Novo Nordisk, the current patent holder.
Sun Pharma must first secure a manufacturing license for the diabetes drug. The company is required to return to court for final authorization before marketing the tablets.
This legal hurdle potentially delays Sun Pharma's entry into the lucrative semaglutide market. Company representatives are scheduled to meet investors and analysts at the Emkay Confluence event in Mumbai today.